Quarterly ResultMay 12, 2026, 07:42 AM
SAB Biotherapeutics Q1 Net Loss $(18.87)M; Public Offering Raises $86.87M
AI Summary
SAB Biotherapeutics reported a net loss of $(18.87) million for Q1 2026, a significant increase from $(5.20) million in Q1 2025. Despite this, basic and diluted loss per share improved to $(0.35) from $(0.56) due to a substantial increase in weighted-average common shares outstanding. The company bolstered its financial position through a March 2026 public offering, raising approximately $86.87 million in net proceeds, which increased cash and cash equivalents to $20.52 million and total stockholders' equity to $227.25 million.
Key Highlights
- Net loss for Q1 2026 was $(18.87) million, up from $(5.20) million in Q1 2025.
- Basic and diluted loss per share improved to $(0.35) from $(0.56) year-over-year.
- Weighted-average common shares outstanding increased to 53.56 million from 9.29 million.
- March 2026 Public Offering generated $79.64 million, plus $7.24 million from underwriters' option.
- Cash and cash equivalents rose to $20.52 million as of March 31, 2026.
- Total stockholders' equity increased to $227.25 million as of March 31, 2026.
- Research and development expenses grew to $13.40 million from $7.66 million.
- Net cash used in operating activities increased to $(14.27) million.